A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.

Hohendorff, J

A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus. [electronic resource] - Endocrine Aug 2017 - 272-279 p. digital

Publication Type: Journal Article

1559-0100

10.1007/s12020-017-1341-2 doi


Adult
Aged
Benzhydryl Compounds--therapeutic use
Creatinine--blood
Deoxyglucose--blood
Diabetes Mellitus, Type 2--drug therapy
Female
Glucokinase--genetics
Glucosides--therapeutic use
Glycosuria--urine
Hepatocyte Nuclear Factor 1-alpha--genetics
Humans
Hypoglycemic Agents--therapeutic use
Male
Middle Aged
Mutation
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors
Young Adult